OXiGENE is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for treating cancer, with its primary focus on developing vascular disrupting agents that selectively disrupt abnormal blood vessels that are associated with solid tumor progression. The company is devoted to leveraging its intellectual property and therapeutic development expertise to provide patients with life-extending and life-enhancing medicines. For more information, visit the company’s Web site at www.oxigene.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: